ProShare Advisors LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 13.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,603 shares of the company’s stock after selling 3,297 shares during the quarter. ProShare Advisors LLC’s holdings in Sanofi were worth $1,121,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the company. FMR LLC raised its position in Sanofi by 17.0% in the 1st quarter. FMR LLC now owns 23,282,201 shares of the company’s stock valued at $1,267,017,000 after purchasing an additional 3,387,606 shares during the last quarter. Bank of America Corp DE lifted its position in Sanofi by 17.0% during the 1st quarter. Bank of America Corp DE now owns 10,626,939 shares of the company’s stock worth $578,318,000 after buying an additional 1,541,832 shares in the last quarter. BlackRock Inc. grew its holdings in Sanofi by 2.5% during the 1st quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock worth $546,804,000 after acquiring an additional 249,619 shares during the last quarter. Morgan Stanley increased its position in Sanofi by 19.3% in the 4th quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after acquiring an additional 1,251,199 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Sanofi by 11.9% during the first quarter. Bank of New York Mellon Corp now owns 6,273,931 shares of the company’s stock worth $341,427,000 after purchasing an additional 667,195 shares in the last quarter. Institutional investors own 10.06% of the company’s stock.
Analysts Set New Price Targets
Several research firms recently weighed in on SNY. HSBC initiated coverage on shares of Sanofi in a research report on Friday, July 14th. They issued a “buy” rating for the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 29th. Finally, Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average target price of $72.50.
Sanofi Price Performance
Sanofi stock opened at $55.20 on Thursday. The company has a current ratio of 1.21, a quick ratio of 0.81 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $139.37 billion, a P/E ratio of 18.90, a PEG ratio of 1.57 and a beta of 0.57. The business has a 50-day moving average of $53.25 and a 200-day moving average of $53.63. Sanofi has a 1 year low of $36.91 and a 1 year high of $57.82.
Sanofi (NASDAQ:SNY – Get Free Report) last issued its earnings results on Friday, July 28th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.88 by $0.07. Sanofi had a net margin of 16.07% and a return on equity of 27.94%. The firm had revenue of $10.85 billion during the quarter, compared to the consensus estimate of $11.47 billion. On average, equities analysts anticipate that Sanofi will post 4.44 EPS for the current year.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.